PE20190414A1 - Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) - Google Patents
Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)Info
- Publication number
- PE20190414A1 PE20190414A1 PE2019000271A PE2019000271A PE20190414A1 PE 20190414 A1 PE20190414 A1 PE 20190414A1 PE 2019000271 A PE2019000271 A PE 2019000271A PE 2019000271 A PE2019000271 A PE 2019000271A PE 20190414 A1 PE20190414 A1 PE 20190414A1
- Authority
- PE
- Peru
- Prior art keywords
- ghrelin
- goat
- aciltransferase
- inhibitors
- oxadiazolopyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Referido a derivados de oxadiazolopiridina de formula (I), en donde X es CH o N; R1 se selecciona entre CH3, -CH2OH y Cl; R2 se selecciona, independientemente entre si, entre H, F, Cl, Br, I, CN, C1-6-alquilo, C3-7-cicloalquilo, entre otros; n es 1, 2 o 3. Estos compuestos se fijan a ghrelin O-acil transferasa (GOAT) e inhiben su actividad. Tambien se refiere a metodos de fabricacion y su uso adecuado para el tratamiento y la prevencion de enfermedades, tales como enfermedades metabolicas, diabetes mellitus tipo 2, la obesidad, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16183047 | 2016-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190414A1 true PE20190414A1 (es) | 2019-03-19 |
Family
ID=56609762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019000271A PE20190414A1 (es) | 2016-08-05 | 2017-07-31 | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) |
Country Status (32)
Country | Link |
---|---|
US (3) | US9994591B2 (es) |
EP (1) | EP3494120B1 (es) |
JP (1) | JP6651054B2 (es) |
KR (1) | KR102496075B1 (es) |
CN (1) | CN109843891B (es) |
AR (1) | AR109296A1 (es) |
AU (1) | AU2017307033B2 (es) |
CA (1) | CA3033058A1 (es) |
CL (1) | CL2019000274A1 (es) |
CO (1) | CO2019000601A2 (es) |
CY (1) | CY1124381T1 (es) |
DK (1) | DK3494120T3 (es) |
EA (1) | EA037277B1 (es) |
ES (1) | ES2874587T3 (es) |
HR (1) | HRP20210908T1 (es) |
HU (1) | HUE054928T2 (es) |
IL (1) | IL264506B (es) |
LT (1) | LT3494120T (es) |
MA (1) | MA45843B1 (es) |
MX (1) | MX2019001427A (es) |
MY (1) | MY197064A (es) |
PE (1) | PE20190414A1 (es) |
PH (1) | PH12019500254A1 (es) |
PL (1) | PL3494120T3 (es) |
PT (1) | PT3494120T (es) |
RS (1) | RS61937B1 (es) |
SA (1) | SA519401039B1 (es) |
SG (1) | SG11201811804QA (es) |
SI (1) | SI3494120T1 (es) |
TW (1) | TWI749042B (es) |
UA (1) | UA124267C2 (es) |
WO (1) | WO2018024653A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7225253B2 (ja) * | 2018-02-02 | 2023-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体 |
AU2019215709A1 (en) * | 2018-02-02 | 2020-07-16 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
SG11202006125VA (en) * | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
EP4153599B1 (en) | 2020-05-22 | 2024-03-13 | Boehringer Ingelheim International GmbH | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
JP2023526353A (ja) | 2020-05-22 | 2023-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの連続製造方法 |
CN112014340A (zh) * | 2020-09-01 | 2020-12-01 | 广西玮美生物科技有限公司 | 非人灵长类动物胃饥饿素的检测方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
CL2007003580A1 (es) | 2006-12-11 | 2009-03-27 | Boehringer Ingelheim Int | Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes. |
CN101790538B (zh) | 2007-02-15 | 2014-07-30 | 印第安纳大学研究与科技公司 | 胰高血糖素/glp-1受体共激动剂 |
US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
JP5635530B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
MA32970B1 (fr) | 2008-12-15 | 2012-01-02 | Zealand Pharma As | Analogues du glucagon |
JP5635532B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
SG177609A1 (en) | 2009-07-13 | 2012-02-28 | Zealand Pharma As | Acylated glucagon analogues |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
US9169310B2 (en) | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
BR112014015681A2 (pt) | 2011-12-23 | 2019-09-24 | Boehringer Ingelheim Int | análogos de glucagon |
CN104254525B (zh) * | 2012-02-24 | 2016-05-25 | 武田药品工业株式会社 | 芳环化合物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
WO2016044467A1 (en) * | 2014-09-17 | 2016-03-24 | The Regents Of The University Of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
SG11202006125VA (en) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
AU2019215709A1 (en) | 2018-02-02 | 2020-07-16 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
JP7225253B2 (ja) * | 2018-02-02 | 2023-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体 |
-
2017
- 2017-07-31 MY MYPI2018002719A patent/MY197064A/en unknown
- 2017-07-31 AU AU2017307033A patent/AU2017307033B2/en active Active
- 2017-07-31 RS RS20210702A patent/RS61937B1/sr unknown
- 2017-07-31 PE PE2019000271A patent/PE20190414A1/es unknown
- 2017-07-31 CN CN201780047100.1A patent/CN109843891B/zh active Active
- 2017-07-31 PT PT177430642T patent/PT3494120T/pt unknown
- 2017-07-31 CA CA3033058A patent/CA3033058A1/en active Pending
- 2017-07-31 EP EP17743064.2A patent/EP3494120B1/en active Active
- 2017-07-31 LT LTEP17743064.2T patent/LT3494120T/lt unknown
- 2017-07-31 SI SI201730770T patent/SI3494120T1/sl unknown
- 2017-07-31 SG SG11201811804QA patent/SG11201811804QA/en unknown
- 2017-07-31 PL PL17743064T patent/PL3494120T3/pl unknown
- 2017-07-31 WO PCT/EP2017/069274 patent/WO2018024653A1/en unknown
- 2017-07-31 JP JP2019506164A patent/JP6651054B2/ja active Active
- 2017-07-31 HU HUE17743064A patent/HUE054928T2/hu unknown
- 2017-07-31 EA EA201990418A patent/EA037277B1/ru not_active IP Right Cessation
- 2017-07-31 US US15/664,119 patent/US9994591B2/en active Active
- 2017-07-31 MA MA45843A patent/MA45843B1/fr unknown
- 2017-07-31 UA UAA201901840A patent/UA124267C2/uk unknown
- 2017-07-31 MX MX2019001427A patent/MX2019001427A/es unknown
- 2017-07-31 DK DK17743064.2T patent/DK3494120T3/da active
- 2017-07-31 KR KR1020197006448A patent/KR102496075B1/ko active IP Right Grant
- 2017-07-31 ES ES17743064T patent/ES2874587T3/es active Active
- 2017-08-04 TW TW106126319A patent/TWI749042B/zh active
- 2017-08-04 AR ARP170102213A patent/AR109296A1/es unknown
-
2018
- 2018-05-09 US US15/974,882 patent/US10308667B2/en not_active Ceased
-
2019
- 2019-01-22 CO CONC2019/0000601A patent/CO2019000601A2/es unknown
- 2019-01-28 IL IL264506A patent/IL264506B/en active IP Right Grant
- 2019-02-01 CL CL2019000274A patent/CL2019000274A1/es unknown
- 2019-02-05 SA SA519401039A patent/SA519401039B1/ar unknown
- 2019-02-06 PH PH12019500254A patent/PH12019500254A1/en unknown
-
2020
- 2020-10-14 US US17/069,940 patent/USRE49446E1/en active Active
-
2021
- 2021-06-08 HR HRP20210908TT patent/HRP20210908T1/hr unknown
- 2021-06-14 CY CY20211100525T patent/CY1124381T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190414A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
CO2020010465A2 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
CR11183A (es) | Espirociclos como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa de tipo 1 | |
PE20190518A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
UY37272A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
DOP2017000066A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
GT201300324A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
CU20160149A7 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
PA8848201A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
CR20130409A (es) | Novedosos derivados de azabencimidazolcíclico útiles como agentes antidiabéticos | |
GT201400089A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
CU20160120A7 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
CU20090132A7 (es) | Compuestos tricíclicos, composiciones y procedimientos | |
CO2018005315A2 (es) | Moduladores de la interacción de sestrina-gator2 y sus usos | |
PA8809001A1 (es) | Compuestos organicos | |
CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
PE20141940A1 (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos |